Orchestra BioMed (OBIO) stake rises to 19.2% after RTW warrant exercise
Rhea-AI Filing Summary
RTW Investments and affiliated funds updated their ownership report on Orchestra BioMed Holdings after exercising pre-funded warrants. On April 27, 2026, the RTW funds exercised pre-funded warrants for 1,250,032 shares at $0.0001 per share on a cashless basis, leading to 1,250,000 new common shares being issued and 32 shares withheld to cover the exercise price.
Following these transactions and including certain additional warrants exercisable within 60 days, RTW Investments and Dr. Roderick Wong are reported as beneficial owners of 11,942,394 shares of common stock, representing 19.2% of Orchestra BioMed’s outstanding common stock as calculated in the filing.
Positive
- None.
Negative
- None.
Insights
RTW exercises pre-funded warrants, crystallizing a 19.2% Orchestra BioMed stake.
The filing shows RTW-managed funds exercising pre-funded warrants to receive 1,250,000 Orchestra BioMed common shares on a cashless basis. This converts a derivative-like claim into actual equity, while pre-funded warrants remain outstanding at the fund level for additional shares.
Post-exercise, RTW Investments and Dr. Roderick Wong are reported as beneficial owners of 11,942,394 shares, or 19.2% of the company’s common stock, based on the share count methodology disclosed. This reflects a large, concentrated institutional position rather than a new investment thesis shift disclosed in the excerpt.
Key Figures
Key Terms
Pre-Funded Warrants financial
cashless basis financial
beneficially owned financial
Schedule 13D regulatory
investment manager financial
AI-generated analysis. How Rhea-AI works. Not financial advice.